Ixazomib Granted Conditional European Approval for Myeloma

The European Commission has granted a conditional approval to ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone for adult patients with multiple myeloma following at least 1 prior therapy, based on a near 6-month improvement in progression-free survival (PFS) in the phase III TOURMALINE-MM1 study. In the pivotal study, the median PFS with the ixazomib triplet was 20.6 months compared with 14.7 months with lenalidomide and dexamethasone … (leggi tutto)